TapewireFind a company

person · Reporting owner

Goeltz II Robert C.

Disclosed activity across 3 companies

Tapewire entity
47978
SEC CIK
0001653881

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Arcus Biosciences, Inc.RCUS · Entity 4104Chief Financial OfficerMay 11, 2026May 12, 2026
Unity Biotechnology, Inc.UBX · Entity 77428Chief Financial OfficerJune 22, 2020June 24, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcus Biosciences, Inc.

Report date May 11, 2026 · Filed May 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect84,161 Reported balance After 2026-05-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-05-11 · Sale · Disposed 7,763 · Balance 84,161

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Includes the unvested portion of the reporting person's RSU grants.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Includes the unvested portion of the reporting person's RSU grants.

Unity Biotechnology, Inc.

Report date June 22, 2020 · Filed June 24, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivativeDirect161,027 Reported balance After 2020-06-22 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2020-06-22 · Tax withholding · Disposed 2,483 · Balance 161,027

F1: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting.

F2: Includes Restricted Stock Units which vest over time measured from the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting.

F2: Includes Restricted Stock Units which vest over time measured from the grant date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CytomX Therapeutics, Inc.

Report date May 12, 2017 · Filed May 16, 2017

Section 16 reporting ended · disclosed 2017-05-16. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect32,756 Ending reported balance After 2017-05-12 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2017-05-12 · Exercise / conversion · Acquired 9,980 · Balance 22,769

Row 2 · 2017-05-12 · Exercise / conversion · Acquired 9,987 · Balance 32,756

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2025-05-06Direct204,678 Reported balance After 2017-05-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2017-05-12 · Exercise / conversion · Disposed 9,980 · Balance 204,678

F1: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2025-08-25Direct85,891 Reported balance After 2017-05-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2017-05-12 · Exercise / conversion · Disposed 9,987 · Balance 85,891

F2: This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019.

F2: This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 11, 2026 Filed May 12, 2026 20:09 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 7,763 $25.63 $198,965.69
Disclosure

SEC source: 0001653881-26-000005 · wk-form4_1778616546.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,161

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · balance_after: Includes the unvested portion of the reporting person's RSU grants.

Read SEC document
January 23, 2026 Filed Jan 27, 2026 01:21 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 96,000 $0.00 Strike: $22.13 $0.00
Disclosure

SEC source: 0001653881-26-000002 · wk-form4_1769476886.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock · 96,000 shares

Expires 2036-01-22

F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2026 Filed Jan 27, 2026 01:21 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 24,000 $0.00 $0.00
Disclosure

SEC source: 0001653881-26-000002 · wk-form4_1769476886.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,924

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants.

Read SEC document
December 31, 2025 Filed Jan 2, 2026 21:19 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 6,552 $23.38 $153,185.76
Disclosure

SEC source: 0001610717-26-000002 · form4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,924

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
December 17, 2025 Filed Dec 18, 2025 22:35 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 5,960 $22.16 $132,070.62
Disclosure

SEC source: 0001653881-25-000011 · wk-form4_1766097319.xml · nonDerivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,476

F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants.

Read SEC document
December 16, 2025 Filed Dec 18, 2025 22:35 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 6,702 $21.88 $146,668.58
Disclosure

SEC source: 0001653881-25-000011 · wk-form4_1766097319.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,436

F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants.

Read SEC document
November 26, 2025 Filed Nov 26, 2025 21:07 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 5,000 $25.00 $125,000.00
Disclosure

SEC source: 0001653881-25-000007 · wk-form4_1764191259.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,138

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
October 28, 2025 Filed Oct 29, 2025 12:54 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 5,000 $20.00 $100,000.00
Disclosure

SEC source: 0001653881-25-000005 · wk-form4_1761742455.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,138

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023.

Read SEC document
January 23, 2025 Filed Jan 27, 2025 21:30 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 150,000 $0.00 Strike: $13.33 $0.00
Disclosure

SEC source: 0001724521-25-000017 · wk-form4_1738013415.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2025-01-22

F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2025 Filed Jan 27, 2025 21:30 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 37,000 $0.00 $0.00
Disclosure

SEC source: 0001724521-25-000017 · wk-form4_1738013415.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,138

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company.

Read SEC document
December 31, 2024 Filed Jan 3, 2025 21:08 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 3,594 $15.00 $53,910.00
Disclosure

SEC source: 0001724521-25-000002 · wk-form4_1735938476.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,138

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023.

Read SEC document
December 15, 2024 Filed Dec 18, 2024 01:36 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Tax withholdingCommon Stock 10,099 $16.08 $162,391.92
Disclosure

SEC source: 0001724521-24-000180 · wk-form4_1734485773.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,732

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:40 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 86,600 $0.00 Strike: $15.44 $0.00
Disclosure

SEC source: 0001724521-24-000030 · wk-form4_1706229604.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,600

Underlying: Common Stock · 86,600 shares

Expires 2034-01-22

F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2024 Filed Jan 26, 2024 00:40 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 21,300 $0.00 $0.00
Disclosure

SEC source: 0001724521-24-000030 · wk-form4_1706229604.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,131

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2024 Filed Feb 23, 2024 22:49 UTC Amendment Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 22,000 $0.00 $0.00
Disclosure

SEC source: 0001724521-24-000057 · wk-form4a_1708728574.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,831

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 2,004 $20.00 $40,080.00
Disclosure

SEC source: 0001724521-24-000009 · wk-form4_1704406978.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,831

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023.

Read SEC document
December 19, 2023 Filed Dec 20, 2023 21:10 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Disposition to issuerCommon Stock 2,808 $18.09 $50,796.72
Disclosure

SEC source: 0001724521-23-000067 · wk-form4_1703106591.xml · nonDerivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,835

F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 18, 2023 Filed Dec 20, 2023 21:10 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 Disposition to issuerCommon Stock 2,749 $17.74 $48,767.26
Disclosure

SEC source: 0001724521-23-000067 · wk-form4_1703106591.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,643

F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:05 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 4,049 $20.04 $81,141.96
Disclosure

SEC source: 0001209191-23-035740 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,392

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 22:53 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 138,200 $0.00 Strike: $22.02 $0.00
Disclosure

SEC source: 0001209191-23-004875 · doc4.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,200

Underlying: Common Stock · 138,200 shares

Expires 2033-01-22

F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 22:53 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 34,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004875 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,441

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company.

Read SEC document
December 16, 2022 Filed Dec 17, 2022 02:44 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 387 $31.23 $12,086.01
Disclosure

SEC source: 0001209191-22-061762 · doc4.xml · nonDerivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,566

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 16, 2022 Filed Dec 17, 2022 02:44 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 2,066 $30.66 $63,343.56
Disclosure

SEC source: 0001209191-22-061762 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,953

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
March 08, 2022 Filed Mar 10, 2022 22:08 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 62,500 $0.00 Strike: $33.03 $0.00
Disclosure

SEC source: 0001209191-22-017984 · doc4.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2032-03-07

F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company.

Read SEC document
March 08, 2022 Filed Mar 10, 2022 22:08 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 15,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017984 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,519

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 21:22 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 224 $41.42 $9,278.93
Disclosure

SEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 6

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,019

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 21:22 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 171 $40.57 $6,938.02
Disclosure

SEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 5

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,243

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $41.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 21:22 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 88 $39.67 $3,491.13
Disclosure

SEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 4

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,414

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 21:22 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 138 $38.79 $5,352.70
Disclosure

SEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 3

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,502

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 16, 2021 Filed Dec 20, 2021 21:22 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 131 $40.46 $5,299.80
Disclosure

SEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,640

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 16, 2021 Filed Dec 20, 2021 21:22 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 354 $39.59 $14,015.43
Disclosure

SEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,771

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:10 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 75,000 $0.00 Strike: $36.73 $0.00
Disclosure

SEC source: 0001209191-21-004260 · doc4.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2031-01-18

F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:10 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 12,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-004260 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company.

Read SEC document
September 09, 2020 Filed Sep 9, 2020 20:53 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 5,000 $21.57 $107,848.50
Disclosure

SEC source: 0001209191-20-049846 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.10 to $22.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 03, 2020 Filed Aug 4, 2020 22:53 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 250,000 $0.00 Strike: $21.06 $0.00
Disclosure

SEC source: 0001209191-20-044848 · doc4.xml · derivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2030-07-31

F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after August 1, 2020, subject to the Reporting Person's continued service to the Company.

Read SEC document
June 22, 2020 Filed Jun 24, 2020 17:03 UTC Unity Biotechnology, Inc. UBX · Entity 77428 Tax withholdingCommon Stock, $0.0001 par value 2,483 $9.67 $24,010.61
Disclosure

SEC source: 0000899243-20-017558 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,027

F1 · kind: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting.

F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date.

Read SEC document
March 30, 2020 Filed Apr 1, 2020 17:16 UTC Unity Biotechnology, Inc. UBX · Entity 77428 GrantStock Option (Right to Buy) · Derivative 118,188 $0.00 Strike: $5.95 $0.00
Disclosure

SEC source: 0000899243-20-009854 · doc4.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,188

Underlying: Common Stock · 118,188 shares

Expires 2030-03-29

F3 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Read SEC document
March 30, 2020 Filed Apr 1, 2020 17:16 UTC Unity Biotechnology, Inc. UBX · Entity 77428 GrantCommon Stock, $0.0001 par value 29,106 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-009854 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,510

F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from March 30, 2020. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

F2 · balance_after: Includes RSUs which vest over time measured from the grant date.

Read SEC document
February 24, 2020 Filed Feb 26, 2020 17:48 UTC Unity Biotechnology, Inc. UBX · Entity 77428 Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $3.43 $0.00
Disclosure

SEC source: 0000899243-20-005933 · doc4.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,620

Underlying: Common Stock · 10,000 shares

Expires 2027-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on September 5, 2018 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Read SEC document
February 24, 2020 Filed Feb 26, 2020 17:48 UTC Unity Biotechnology, Inc. UBX · Entity 77428 Exercise / conversionCommon Stock, $0.0001 par value 10,000 $3.43 $34,300.00
Disclosure

SEC source: 0000899243-20-005933 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,404

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 relates to the exercise of an in-the-money stock option with cash by Reporting Person.

Read SEC document
September 19, 2019 Filed Sep 23, 2019 20:01 UTC Unity Biotechnology, Inc. UBX · Entity 77428 GrantStock Option (Right to Buy) · Derivative 28,814 $0.00 Strike: $3.43 $0.00
Disclosure

SEC source: 0000899243-19-024074 · doc4.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,814

Underlying: Common Stock · 28,814 shares

Expires 2027-09-25

F2 · shares: On September 26, 2017, Reporting Person was granted an option exercisable for 115,254 shares. Twenty-five percent (25%) of the shares was subject to vesting pursuant to the achievement of a clinical development milestone; in this case proof of concept that treatment with a senolytic drug meaningfully ameliorates a human disease. On September 19, 2019, Issuer's Board of Directors determined that such milestone was achieved.

Read SEC document
June 20, 2019 Filed Jun 24, 2019 16:17 UTC Unity Biotechnology, Inc. UBX · Entity 77428 GrantStock Option (Right to Buy) · Derivative 116,850 $0.00 Strike: $9.00 $0.00
Disclosure

SEC source: 0001567619-19-013880 · doc1.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,850

Underlying: Common Stock · 116,850 shares

Expires 2029-06-19

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 48 successive, equal monthly installments measured from June 20, 2019, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Read SEC document
June 20, 2019 Filed Jun 24, 2019 16:17 UTC Unity Biotechnology, Inc. UBX · Entity 77428 GrantCommon Stock 21,075 $0.00 $0.00
Disclosure

SEC source: 0001567619-19-013880 · doc1.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,404

F1 · shares: RSUs which vest 1/3 annually over 3 years measured from June 20, 2019.

F2 · balance_after: Includes 1,981 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2019.

Read SEC document
October 10, 2018 Filed Oct 12, 2018 17:36 UTC Unity Biotechnology, Inc. UBX · Entity 77428 Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $3.43 $0.00
Disclosure

SEC source: 0000899243-18-026655 · doc4.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,620

Underlying: Common Stock · 5,000 shares

Expires 2027-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on September 5, 2018 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Read SEC document
October 10, 2018 Filed Oct 12, 2018 17:36 UTC Unity Biotechnology, Inc. UBX · Entity 77428 Exercise / conversionCommon Stock, $0.0001 par value 5,000 $3.43 $17,150.00
Disclosure

SEC source: 0000899243-18-026655 · doc4.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 07, 2018 Filed May 7, 2018 18:24 UTC Unity Biotechnology, Inc. UBX · Entity 77428 ConversionSeries C Preferred Stock · Derivative 1,630 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-18-022049 · doc1.xml · derivative · entry 2

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,630 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.

F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.

F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.

F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities.

Read SEC document
May 07, 2018 Filed May 7, 2018 18:24 UTC Unity Biotechnology, Inc. UBX · Entity 77428 ConversionCommon Stock 1,630 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-18-022049 · doc1.xml · nonDerivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.

Read SEC document
May 02, 2018 Filed May 4, 2018 18:26 UTC Unity Biotechnology, Inc. UBX · Entity 77428 GrantStock Option (Right to Buy) · Derivative 30,508 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0001140361-18-021820 · doc1.xml · derivative · entry 1

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,508

Underlying: Common Stock · 30,508 shares

Expires 2028-05-01

F1 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on the one-year anniversary of May 2, 2018, and 1/48th of the shares shall vest on each monthly anniversary thereafter, subject to the optionee remainining a service provider to the Issuer on each such vesting date.

Read SEC document
May 12, 2017 Filed May 16, 2017 20:57 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 Exercise / conversionStock Option (Right to Buy) · Derivative 9,987 $0.00 Strike: $6.61 $0.00
Disclosure

SEC source: 0001140361-17-021016 · doc1.xml · derivative · entry 4

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,891

Underlying: Common Stock · 9,987 shares

Expires 2025-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015.

Read SEC document
May 12, 2017 Filed May 16, 2017 20:57 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 Exercise / conversionStock Option (Right to Buy) · Derivative 9,980 $0.00 Strike: $4.47 $0.00
Disclosure

SEC source: 0001140361-17-021016 · doc1.xml · derivative · entry 3

Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,678

Underlying: Common Stock · 9,980 shares

Expires 2025-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.